Mobidiag announces new record-setting rapid diagnostics product for bone and joint infections, new microarray-based technology platform and excellent clinical performance of its herpesviral diagnostics product
Helsinki, Finland 16 May – the Finnish biotech company Mobidiag announced today two extensions to its record breaking product family as well as excellent results from clinical evaluation of its Prove-it™ Herpes rapid diagnostics product. Mobidiag’s new Prove-it™ Bone and Joint assay identifies bacteria responsible for bone and joint infections. The product adds new capabilities to Mobidiag’s microarray platform, which can now detect a world record of 64 dangerous bacteria in a single test. Mobidiag’s new Prove-it™ StripArray platform enables further extension of assay content and high throughput. The company also announced excellent clinical evaluation results of its Prove-it™ Herpes microarray assay: the product showed sensitivity and specificity equaling or surpassing current methods and found several herpes infections that current tests missed.
Read the whole press release here.